title: [Hydronephrosis as a prognostic factor for patients of figo IIIB cervical cancer].
abstract: OBJECTIVE
  The aim of this study was to assess whether hydronephrosis is a prognostic factor for patients of FIGO stage III B cervical cancer.
  
  
  METHODS
  A retrospective review of 145 stage III B cervical cancer patients treated with radiotherapy between 1989-1993 at Maria Skłodowska-Curie Memorial Cancer Center in Warsaw was performed. Radiotherapy consisted of External Beam Irradiation (EBI) and Brachytherapy (BT) or EBI alone.
  
  
  RESULTS
  Multivariate analysis revealed that hydronephrosis and Brachytherapy following EBI as the second part of the treatment were statistically significant factors in survival of FIGO stage III B cervical cancer patients. The five-year survival rate was 36% for patients without hydronephrosis treated with EBI and BT, compared to the group with hydronephrosis treated with EBI alone (no regression or too slow regression of the tumor to use BT), in which the survival rate was only 17 months.
  
  
  CONCLUSIONS
  FIGO III b cervical cancer patients with hydronephrosis are treated only with palliative intent.
authors.affiliation: Kliniki Nowotworów Narzadów Płciowych Kobiecych Centrum Onkologii-Instytut w Warszawie.
authors.forename: Ryszard
authors.initials: R
authors.lastname: Krynicki
authors.forename: Mariusz
authors.initials: M
authors.lastname: Bidziński
authors.forename: Waldemar
authors.initials: W
authors.lastname: Wierzba
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Panek
authors.forename: Joanna
authors.initials: J
authors.lastname: Jońska
authors.forename: Bogusław
authors.initials: B
authors.lastname: Lindner
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000379:methods; D018572:Disease-Free Survival; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D006869:Hydronephrosis / Q000209:etiology*; D008875:Middle Aged; D009367:Neoplasm Staging; D011044:Poland; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000150:complications* / Q000532:radiotherapy*
vernacular_title: Zastój moczu jako czynnik prognostyczny u chorych na raka szyjki macicy w IIIB stopniu klinicznego zaawansowania.